TITLE

Prostate cancer: 9. Treatment of advanced disease

AUTHOR(S)
Gleave, Martin E.; Bruchovsky, Nick; Moore, Malcolm J.; Venner, Peter
PUB. DATE
January 1999
SOURCE
CMAJ: Canadian Medical Association Journal;1/26/99, Vol. 160 Issue 2, p225
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the treatment of advanced prostate cancer. The case of a 70-year-old man; Details about androgens and the prostate gland; Androgen withdrawal therapy; Responses to androgen withdrawal therapy; Controversial issues in advanced prostate cancer; Quality-of-life issues; Hormone-refractory prostate cancer.
ACCESSION #
1491990

 

Related Articles

  • Solving enigma of prostate cancer takes varied paths. Manyak, MD, Michael J. // Urology Times;May2001, Vol. 29 Issue 5, p2 

    Comments on the diversity of approaches for the management of prostate cancer. Improvements in treatment outcomes due to earlier diagnosis; Quest for new prostate cancer biomarkers; Investigation of inflammation as a precursor to prostate cancer development.

  • Paradigm shift underway in PCa treatment. Prescott, Lawrence M. // Urology Times;May2001, Vol. 29 Issue 5, p9 

    Investigates a paradigm shift from the 'seek and destroy' to 'command and control' treatment of prostate cancer. Therapies being developed targeting the genetic, molecular and cellular mechanisms that regulate cancer progression; Biologic mechanisms responsible for tumor progression providing...

  • Study Examines Long-Term Outcomes After Prostate Cancer Diagnosis. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;6/1/2005, Vol. 97 Issue 11, p795 

    Reports that men with low-grade prostate cancer have a low risk of dying from the disease, according to results from a long-term study. Retrospective, population-based cohort study of men diagnosed with clinically localized prostate cancer between 1971 and 1984; Observation that the data do not...

  • Solo epothilone yields 21% response rate in AIPC. Helwick, Caroline // Urology Times;3/1/2009, Vol. 37 Issue 3, p1 

    The article presents the result of the U.S. multicenter phase II study analyzing the impact of sagopilone, the first synthetic epothilone, on the prostate specific antigen (PSA) in men with androgen-independent prostate cancer. The study shows that the novel agent sagopilone proves to have...

  • Experimental prostate cancer drugs slow disease progression. Stephenson, Joan; Stephenson, J // JAMA: Journal of the American Medical Association;7/4/2001, Vol. 286 Issue 1, p34 

    Reports on an agent which shows promise in reducing bone loss and delaying progression of disease in men with advanced prostate cancer. Drug which is intended to target one of the specific molecular pathways that allow cancerous cells to survive and spread; Design of the drug astrasentan to...

  • TRT and prostate cancer: The focus is shifting. Mulcahy, John J. // Urology Times;2/1/2009, Vol. 37 Issue 2, p4 

    The article presents the author's views on the efficacy of testosterone replacement therapy (TRT) in men with advanced prostate cancer. He mentions that such therapy is often recommended to persons having symptoms of hypogonadism or low serum testosterone associated with the unpleasant sequelae...

  • Post-RP patients report satisfaction with injections. Gagnon, Louise // Urology Times;2/1/2009, Vol. 37 Issue 2, p9 

    The article provides information on medical studies presented at the 2008 Fall Scientific Meeting of the Sexual Medicine Society of North America Inc. concerning the satisfaction of men who turn to intracavernosal injection (ICI) therapy following prostate surgery. According to physician Nelson...

  • Pilot study shows combination therapy containing Quadramet impacts prostate specific antigen levels.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p24 

    Presents the results of a pilot study showing that combination therapy containing Quaramet and Taxotere increases prostate specific antigen levels. Preliminary data showing that the combination is simple and efficient.

  • Praecis makes first European regulatory submission for Plenaxis.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p25 

    Reports that Praecis Pharmaceuticals has begun the European regulatory process for its Plenaxis product in treating prostate cancer. Marketing Authorization Application process.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics